Showing results (21-30 of 88) with videos related to

Sort By:
Pageof 9
Asian Pacific Journal of Cancer Prevention : APJCP|April 5, 2016
Prostatic Bleeding after Prostatic Biopsy Effects Oncological Outcomes with Laparoscopic Radical ProstatectomyTomoaki Takai, Teruo Inamoto, Kazumasa Komura, et al.
Oncology|April 7, 2026
Hypoxia-Induced microRNAs confer survival advantage in bladder cancer by fine-tuning oncogenic PathwaysTakaya Ohno, Yuki Nakajima, Yuki Yoshikawa, et al.
Current Urology|October 12, 2019
Influence of the Body Mass Index and its Effect on Tumor Characteristics and Survival among a Population with Access to Surgical Management of Upper Tract Urothelial CarcinomaTeruo Inamoto, Naoto Sassa, Ryohei Hattori, et al.
In Vivo (Athens, Greece)|April 28, 2025
Cancer-induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab VedotinMamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 14, 2025
Comparison of Oncological Outcomes of Conventional Androgen Deprivation Therapy (ADT) and ADT Plus Androgen Receptor Signaling Inhibitor in Older Patients With Metastatic Castration-Sensitive Prostate CancerYutaka Yamamoto, Saizo Fujimoto, Mamoru Hashimoto, et al.
Translational Andrology and Urology|September 15, 2025
Upper urinary tract urothelial carcinoma patients show better overall response rate than bladder cancer patients during enfortumab vedotin treatment following pembrolizumabMamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, et al.
International Journal of Clinical Oncology|October 1, 2024
Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitorYutaka Yamamoto, Saizo Fujimoto, Mamoru Hashimoto, et al.
Scientific Reports|January 13, 2026
Comparative efficacy of immune checkpoint inhibitor combination therapies by metastatic site in metastatic renal cell carcinomaShingo Toyoda, Lan Inoki, Mamoru Hashimoto, et al.
Science Advances|April 23, 2025
Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancerFu Gui, Baishan Jiang, Jie Jiang, et al.
Biorxiv : the Preprint Server for Biology|July 19, 2024
Acute BRCAness Induction and AR Signaling Blockage through CDK12/7/9 Degradation Enhances PARP Inhibitor Sensitivity in Prostate CancerFu Gui, Baishan Jiang, Jie Jiang, et al.
Pageof 9